Lupus & antiphospholipid syndrome
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature
Authors' conclusion
Baseline SLEDAI-2K ≥10 was associated with shorter disease duration and more severe flares. IFNGS-high patients were younger at diagnosis and had distinct patterns of organ involvement, compared with IFNGS-low patients.
Study context
- Population
- Patients with SLE (Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) criteria), 135 centres in 8 countries, June 2017 to November 202293.2% female
- Participants
- 823 patients
- Exposure
- SLEDAI-2K ≥10 vs <10; IFNGS-high vs IFNGS-low
- SLEDAI-2K ≥10n = 241
- IFNGS-highn = 522
- Outcome
- Baseline characteristics by SLEDAI-2K and IFNGS status
- Follow-up
- Baseline
Methodological detailsSPOCS, international, multicentre (135 centres in 8 countries), descriptive analysis
- SPOCS
- International
- Multicentre (135 centres in 8 countries)
- Descriptive analysis
Main finding
As reported in the abstract
baseline
Mean (SD) age, years
45.3
13.9
Years since diagnosis, mean (SD)
11.1
9.2
Baseline SLICC/ACR DI score ≥1
52.4%
Observational data: associations, not effects.
Further findings
| Outcome | SLEDAI-2K ≥10 | SLEDAI-2K <10 | IFNGS-high | IFNGS-low | P value |
|---|---|---|---|---|---|
| Age, years · baselineSLEDAI-2K ≥10 vs SLEDAI-2K <10 · mean, years | 42.8 (SD 13.7) | 46.6 (SD 14.2) | — not stated in the abstract | — not stated in the abstract | nominal p=0.001 |
| SLE duration, years · baselineSLEDAI-2K ≥10 vs SLEDAI-2K <10 | 10.4 (SD 8.6) years | 12.4 (SD 9.6) years | — not stated in the abstract | — not stated in the abstract | nominal p=0.012 |
| Severe flaresSLEDAI-2K ≥10 vs SLEDAI-2K <10 | 12.9% | 5.3% | — not stated in the abstract | — not stated in the abstract | nominal p=0.001 |
| Age at first SLE manifestation, yearsIFNGS-high vs IFNGS-low | — not stated in the abstract | — not stated in the abstract | 30.0 (SD 12.7) years | 36.8 (SD 14.6) years | nominal p<0.001 |
| Haematological involvement | — not stated in the abstract | — not stated in the abstract | 12.6% | 4.1% | |
| Immunological involvement | — not stated in the abstract | — not stated in the abstract | 74.4% | 45.6% | |
| Dermal involvement | — not stated in the abstract | — not stated in the abstract | 69.7% | 62.2% |
— not stated in the abstract
Proportion IFNGS-high by race
- Asian
- 83.3%
- Black
- 86.5%
- White
- 63.5%
- Difference by race
- nominal p<0.001
Original publication
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature. Lupus Sci Med. Published 20 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →